NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.86
+0.38 (2.31%)
At close: Nov 20, 2024, 4:00 PM
17.08
+0.22 (1.30%)
Pre-market: Nov 21, 2024, 7:41 AM EST
NovoCure Employees
NovoCure had 1,453 employees as of December 31, 2023. The number of employees increased by 133 or 10.08% compared to the previous year.
Employees
1,453
Change (1Y)
133
Growth (1Y)
10.08%
Revenue / Employee
$397,617
Profits / Employee
-$103,086
Market Cap
1.82B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Patterson Companies | 7,600 |
Evotec SE | 5,061 |
Integra LifeSciences Holdings | 3,946 |
AtriCure | 1,200 |
RxSight | 374 |
Harmony Biosciences Holdings | 246 |
Tarsus Pharmaceuticals | 244 |
Structure Therapeutics | 93 |
NVCR News
- 3 hours ago - Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma - Business Wire
- 3 hours ago - FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma - Business Wire
- 21 days ago - NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 22 days ago - Novocure Appoints Christoph Brackmann as Chief Financial Officer - Business Wire
- 22 days ago - Novocure Reports Third Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - NovoCure: There Is Still More Upside - Seeking Alpha
- 5 weeks ago - FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients - Benzinga
- 5 weeks ago - FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer - Business Wire